Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma

Journal of Hepatology

Volumn 57, Issue 3, 2012, Pages 592-599

  Sieghart, Wolfgang ^a   Pinter, Matthias ^a   Dauser, Bernhard ^b   Rohr Udilova, Natalya ^a   Piguet, Anne Christine ^c,d   Prager, Gerald ^a   Hayden, Hubert ^a   Dienes, Hans Peter ^a   Dufour, Jean Francois ^c,d   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^c UNIVERSITY OF BERN   (Switzerland)

^d Inselspital   (Switzerland)

Author keywords

Erlotinib; Hepatocellular carcinoma; Sorafenib

Indexed keywords

ERLOTINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; DRUG TREATMENT FAILURE; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RING;

ANIMALS; APOPTOSIS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL SURVIVAL; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PYRIDINES; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865107387     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.04.034     Document Type: Article

References (32)

1. J. Bruix, L. Boix, M. Sala, and J.M. Llovet Focus on hepatocellular carcinoma Cancer Cell 5 2004 215 219 (Pubitemid 38402113)
2. F. Hucke, W. Sieghart, M. Schöniger-Hekele, M. Peck-Radosavljevic, and C. Müller Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien. Klin. Wochenschr. 123 2011 542 551
3. L.B. Seeff Introduction: the burden of hepatocellular carcinoma Gastroenterology 127 2004 S1 S4
4. S.M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J.M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 2008 3129 3140
5. L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, and D. Wilkie Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 2006 11851 11858 (Pubitemid 46094197)
6. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.-F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
7. J. Foster, J. Black, C. LeVea, T. Khoury, B. Kuvshinoff, and M. Javle COX-2 Expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival Ann Surg Oncol 14 2007 752 758 (Pubitemid 46175323)
8. A.F. Buckley, L.J. Burgart, V. Sahai, and S. Kakar Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma Am J Clin Pathol 129 2008 245 251 (Pubitemid 352029315)
9. K.K. Tanabe, A. Lemoine, D.M. Finkelstein, H. Kawasaki, T. Fujii, and R.T. Chung Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis JAMA 299 2008 53 60
10. M. Woo Sung, P. Ho Sung, Y. Ki Hoon, P. MinYoung, K. Kyung Ryoul, and J. Kyu Yun Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis Hum Pathol 37 2006 1324 1332
11. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
12. A. Huether, M. Hopfner, A.P. Sutter, D. Schuppan, and H. Scherubl Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics J Hepatol 43 2005 661 669 (Pubitemid 41253234)
13. P.A. Philip, M.R. Mahoney, C. Allmer, J. Thomas, H.C. Pitot, and G. Kim Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 2005 6657 6663 (Pubitemid 46190260)
14. M.B. Thomas, R. Chadha, K. Glover, X. Wang, J. Morris, and T. Brown Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 2007 1059 1067 (Pubitemid 47312872)
15. D. Semela, A.-C. Piguet, M. Kolev, K. Schmitter, R. Hlushchuk, and V. Djonov Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma J Hepatol 46 2007 840 848 (Pubitemid 46529039)
16. M. Hidalgo, L.L. Siu, J. Nemunaitis, J. Rizzo, L.A. Hammond, and C. Takimoto Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 2001 3267 3279 (Pubitemid 32591445)
17. D. Jurek, N. Udilova, A. Jozkowicz, H. Nohl, B. Marian, and R. Schulte-Hermann Dietary lipid hydroperoxides induce expression of vascular endothelial growth factor (VEGF) in human colorectal tumor cells FASEB J 19 2005 97 99 (Pubitemid 40069930)
18. W. Sieghart, D. Losert, S. Strommer, D. Cejka, K. Schmid, and S. Rasoul-Rockenschaub Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy J Hepatol 44 2006 151 157 (Pubitemid 41772529)
19. T. Reiberger, B. Angermayr, P. Schwabl, N. Rohr-Udilova, M. Mitterhauser, and A. Gangl Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats J Hepatol 51 2009 865 873
20. G.W. Prager, E.-M. Lackner, M.-T. Krauth, M. Unseld, M. Poettler, and S. Laffer Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab Mol Oncol 4 2010 150 160
21. A.-C. Piguet, D. Semela, A. Keogh, L. Wilkens, D. Stroka, and C. Stoupis Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma J Hepatol 49 2008 78 87
22. A.-L. Cheng, Y.-K. Kang, Z. Chen, C.-J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
23. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
24. J.M.L. Ebos, C.R. Lee, J.G. Christensen, A.J. Mutsaers, and R.S. Kerbel Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy Proc Natl Acad Sci 104 2007 17069 17074 (Pubitemid 350210993)
25. N. Murukesh, C. Dive, and G.C. Jayson Biomarkers of angiogenesis and their role in the development of VEGF inhibitors Br J Cancer 102 2009 8 18
26. A.B. Siegel, E.I. Cohen, A. Ocean, D. Lehrer, A. Goldenberg, and J.J. Knox Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma J Clin Oncol 26 2008 2992 2998
27. R.T.-P. Poon, I.O.-L. Ng, C. Lau, L.-X. Zhu, W.-C. Yu, and C.-M. Lo Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study Ann Surg 233 2001 227 235 (Pubitemid 32106077)
28. R. Poon, C. Lau, R. Pang, K. Ng, J. Yuen, and S. Fan High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies Ann Surg Oncol 14 2007 1835 1845 (Pubitemid 46870942)
29. X. Li, G.S. Feng, C.S. Zheng, C.K. Zhuo, and X. Liu Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level World J Gastroenterol 10 2004 2878 2882 (Pubitemid 39303010)
30. A. Sergio, C. Cristofori, R. Cardin, G. Pivetta, R. Ragazzi, and A. Baldan Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness Am J Gastroenterol 103 2008 914 921 (Pubitemid 351506379)
31. G. Giannelli, E. Fransvea, C. Bergamini, F. Marinosci, and S. Antonaci Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma Clin Cancer Res 9 2003 3684 3691 (Pubitemid 37169236)
32. G. Giannelli, A. Azzariti, E. Fransvea, L. Porcelli, S. Antonaci, and A. Paradiso Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells Br J Cancer 91 2004 1964 1969 (Pubitemid 40065526)